Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

Purpose The role of carbohydrate antigen (CA) 19-9 in the evaluation of patients with resectable pancreatic cancer treated with neoadjuvant therapy prior to planned surgical resection is unknown. We evaluated CA 19-9 as a marker of therapeutic response, completion of therapy, and survival in patient...

Full description

Saved in:
Bibliographic Details
Main Author: Katz, Matthew (author)
Other Authors: Varadhachary, Gauri (author), Fleming, Jason (author), Wolff, Robert (author), Lee, Jeffrey (author), Pisters, Peter (author), Vauthey, Jean-Nicolas (author), Abdalla, Eddie (author), Sun, Charlotte (author), Wang, Huamin (author), Crane, Christopher (author), Tamm, Eric (author), Abbruzzese, James (author), Evans, Douglas (author)
Format: article
Published: 2010
Online Access:http://hdl.handle.net/10725/2617
http://dx.doi.org/10.1245/s10434-010-0943-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://hdl.handle.net/10725/2617
http://dx.doi.org/10.1245/s10434-010-0943-1

Similar Items